Systemic therapy with androgen deprivation, chemotherapy, and androgen receptor inhibition targets disseminated microscopic disease and circulating tumor cells, while focal ablation of dominant lesions may eradicate potential sources of resistant clones and reduce tumor-derived immunosuppressive signaling. The gene discussed is AR; the disease is neoplasm.